ClinicalTrials.gg
CompletedNCT02963389Updated Jan 15, 2019

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients

A Phase 1 interventional study of Tripegfilgrastim in Solid Tumor and Lymphoma, sponsored by Dong-A ST Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 6 Years to 19 Years. Per ClinicalTrials.gov, last updated 2019-01-15.

Sponsored by Dong-A ST Co., Ltd. · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
6 Years to 19 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing pegfilgrastim in Lymphoma — none open to participants now, 1 under way, none of them phase 3. pegfilgrastim · Lymphoma.

Enrollment
9th of 13
27 · median 41
Started
2016
the only one that year
Phase 1
2 of 13
none open now
Registered
10th of 13
by date
Lead sponsor
1 of 13
Dong-A ST Co., Ltd.

Among the 13 studies testing pegfilgrastim in Lymphoma, this one is the 9th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 1, and was the 10th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

None of the 13 studies testing pegfilgrastim in Lymphoma is open now. The open studies under Lymphoma, anywhere →

About pegfilgrastim

pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 6 Years to 19 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing pegfilgrastim in Lymphoma as a file.
02

Study summary

This is an open-label, single ascending dose study to evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of Tripegfilgrastim in pediatric solid tumor/lymphoma patients

03

Conditions studied

  • Solid Tumor
  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
6 Years to 19 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >=6 and \<19-year-old pediatrics with solid tumor/lymphoma
  • Scheduled for chemotherapy requiring G-CSF support or having given an experience of ANC \< 0.5x10\^9/L
  • > 0.75x10\^9/L, > 75x10\^9/L
  • performance status 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Patients with leukemia, myelodysplastic syndrome or uncontrolled infectious/nervous diseases
  • History of allergy to filgrastim, pegfilgrastim or known to E-coli derived proteins.
  • Women who are pregnant or lactating
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Tripegfilgrastim 60ug/kg, >=6 and <12-year-old patients

    A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy

    Drug: Tripegfilgrastim

  • Experimental
    Tripegfilgrastim 60ug/kg, >=12 and <19-year-old patients

    A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy

    Drug: Tripegfilgrastim

  • Experimental
    Tripegfilgrastim 100ug/kg, >=6 and <12-year-old patients

    A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy

    Drug: Tripegfilgrastim

  • Experimental
    Tripegfilgrastim 100ug/kg, >=12 and <19-year-old patients

    A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy

    Drug: Tripegfilgrastim

Interventions

06

What researchers measure

Primary outcomes

  1. PK parameter

    Time to reach Cmax of Tripegfilgrastim \[Tmax\]

    Time frame: Day 1(Hour 0) ~ Day 21

  2. PK parameter

    Peak plasma concentration of Tripegfilgrastim \[Cmax\]

    Time frame: Day 1(Hour 0) ~ Day 21

  3. PK parameter

    Area under the plasma concentration of Tripegfilgrastim versus time curve \[AUC\]

    Time frame: Day 1(Hour 0) ~ Day 21

  4. PK parameter

    Half-life of Tripegfilgrastim \[T1/2\]

    Time frame: Day 1(Hour 0) ~ Day 21

  5. PK parameter

    The lowest plasma concentration that Tripegfilgrastim reaches before the next dose is administered \[Ctrough\]

    Time frame: Day 1(Hour 0) ~ Day 21

Secondary outcomes

  1. PD parameter

    Peak plasma concentration of Absolute Neutrophil Count \[ANCmax\]

    Time frame: Day 1(Hour 0) ~ Day 14

  2. PD parameter

    Area under the plasma concentration of Absolute Neutrophil Count versus time curve \[AUC(ANC)\]

    Time frame: Day 1(Hour 0) ~ Day 14

  3. PD parameter

    Time to reach Cmax of Absolute Neutrophil Count \[Tmax(ANC)\]

    Time frame: Day 1(Hour 0) ~ Day 14

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, 82, Korea, Republic of
08

References and documents

Publications

  • Lee S, Hong KT, Moon SJ, Choi JY, Hong CR, Shin HY, Cho JY, Jang IJ, Yu KS, Oh J, Kang HJ. Pharmacokinetic and Pharmacodynamic Characteristics of Tripegfilgrastim, a Pegylated G-CSF, in Pediatric Patients with Solid Tumors. Clin Pharmacol Ther. 2022 Jan;111(1):293-301. doi: 10.1002/cpt.2433. Epub 2021 Oct 27. PubMed 34605552 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Nov 2018, 25 months.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 25 months is below that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2016
First posted
Nov 15, 2016
StartActual
Oct 4, 2016
Primary completionActual
Nov 2018
CompletionActual
Nov 2018
Last update
Jan 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02963389
Responsible party
Sponsor
First posted
Nov 15, 2016
Start date
Oct 4, 2016
Primary completion
Nov 2018
Completion
Nov 2018
Last update
Jan 15, 2019
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion